A funny thing happened on the way to that $56,00-a-year Alzheimer’s drug: Payers are reluctant to pay, providers are reluctant to prescribe, and the price is coming down—at least for some patients.
Original source:
https://www.forbes.com/sites/howardgleckman/2021/09/01/with-medicare-undecided-on-whether-to-pay-alzheimers-drug-maker-biogen-offers-free-doses/